Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2021
FDA grants accelerated approval for Alzheimer’s drug
7 June 2021 - Today, the U.S. FDA approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 ...
Posted by Michael Wonder on 07 Jun 2021
Innovative regenerative medicine therapies – patient safety comes first
3 June 2021 - The U.S. FDA continues to facilitate the development and availability of innovative medical products, such as regenerative ...
Posted by Michael Wonder on 06 Jun 2021
The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price.
3 June 2021 - When Amber Freed heard in 2020 that a drug might help save her young child from ...
Posted by Michael Wonder on 06 Jun 2021
FDA’s decision on Biogen Alzheimer’s drug will be a watershed moment for the agency — and the biotech industry
4 June 2021 - In the coming days the FDA will make one of its most important — and controversial — ...
Posted by Michael Wonder on 05 Jun 2021
Alzheimer’s drug poses a dilemma for the FDA
5 June 2021 - If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. ...
Posted by Michael Wonder on 05 Jun 2021
Newly approved obesity drug Wegovy holds promise, but faces reimbursement challenges
5 June 2021 - On 4 June, the FDA approved Novo Nordisk’s obesity drug Wegovy (semaglutide), a glucagon-like peptide 1 receptor ...
Posted by Michael Wonder on 05 Jun 2021
Chimerix receives U.S. FDA approval for Tembexa (brincidofovir) for the treatment of smallpox
4 June 2021 - First smallpox anti-viral approved for all age groups, including infants, and patients who have difficulty swallowing. ...
Posted by Michael Wonder on 05 Jun 2021
FDA approves new drug treatment for chronic weight management, first since 2014
4 June 2021 - Today, the U.S. FDA approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in ...
Posted by Michael Wonder on 04 Jun 2021
FDA approves first treatment for patients with plasminogen deficiency, a rare genetic disorder
4 June 2021 - Today, the U.S. FDA approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type ...
Posted by Michael Wonder on 04 Jun 2021
FDA authorises lower 1,200 mg intravenous and subcutaneous dose of Regen-COV (casirivimab and imevimab) antibody cocktail to treat patients with COVID-19
4 June 2021 - EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalisation or death ...
Posted by Michael Wonder on 03 Jun 2021
HumanFirst joins the FDA, HHS and more than 20 organisations and leading health companies to launch the Digital Health Measurement Collaborative Community
3 June 2021 - Digital Health Measurement Experts will work together to develop best practices and streamline health measurement using digital ...
Posted by Michael Wonder on 03 Jun 2021
The big pharma firm that saw the future
3 June 2021 - Long ago Roche bet on personalised health care. Now its time has come. ...
Posted by Michael Wonder on 03 Jun 2021
U.S. FDA accepts PharmaEssentia’s BLA resubmission for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
3 June 2021 - FDA assigns a new PDUFA action date of 13 November 2021. ...
Posted by Michael Wonder on 03 Jun 2021
Dermavant submits new drug application to FDA for tapinarof cream for the treatment of adults with plaque psoriasis
3 June 2021 - New drug application is supported by positive data from the Phase 3 PSOARING 1 and PSOARING 2 ...
Posted by Michael Wonder on 03 Jun 2021
Protagonist Therapeutics receives FDA breakthrough therapy designation for rusfertide in polycythemia vera
3 June 2021 - Designation further validates registrational path for rusfertide in polycythemia vera and facilitates potentially expedited development and review. ...